Gravity Analytica

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

KYTX 01.06.2025

SERA-AI Powered Highlights

Drug:KYV-101-001 KYV-101

Diseases:stiff-person syndrome

Diseases:multiple sclerosis

Diseases:myasthenia gravis

Diseases:systemic sclerosis

Diseases:lupus nephritis

Date of Upcoming Event:2025-01-13

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our KYTX Tweets

About Gravity Analytica

Recent Filings

EMERYVILLE, Calif.,Jan. 6, 2025/PRNewswire/ --Kyverna Therapeutics, Inc.(Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd AnnualJ.P. Morgan Healthcare Conference.Warner Biddle, Chief Executive Officer of Kyverna, will present its 2025 strategic priorities and key milestones during a presentation onMonday, January 13, 2025, at5:15 p.m. PST.

A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website athttps://ir.kyvernatx.com/. A replay of the webcast will be available on the website for 30 days following the conference.

About Kyverna TherapeuticsKyverna Therapeutics, Inc.(Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials inthe United StatesandGermanyfor patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

For more information, please visithttps://kyvernatx.com.

Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's participation at the 43rd Annual J.P. Morgan Healthcare Conference and the expected discussion of Kyverna's strategic priorities and key anticipated milestones and Kyverna's ongoing clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with theU.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:Investors:InvestorRelations@kyvernatx.comMedia:media@kyvernatx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-302343449.html

SOURCEKyverna Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com